Moderna officer plans 3,471-share stock sale

Moderna, Inc. (MRNA) is the issuer for which officer Shannon Thyme Klinger filed a Rule 144 notice covering planned sales of common stock through Fidelity Brokerage Services LLC.

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) is the issuer for which officer Shannon Thyme Klinger filed a Rule 144 notice covering planned sales of common stock through Fidelity Brokerage Services LLC. The notice relates to 3,471 shares expected to be acquired by stock option exercise and sold for cash on or after 09/01/2026. The filing also cites 399,235,889 common shares outstanding as of 09/01/2026 and reports a prior sale of 3,471 common shares on 06/04/2026 at a stated price of $173,550.00.

Key Figures

Shares to be sold: 3,471 shares of common stock Market value of securities held: $485,766.45 Shares outstanding: 399,235,889 shares +2 more

5 metrics

Shares to be sold 3,471 shares of common stock Planned sale via stock option exercise on or after 09/01/2026

Market value of securities held $485,766.45 Value figure associated with 3,471 Moderna common shares

Shares outstanding 399,235,889 shares Moderna common shares outstanding as of 09/01/2026

Past 3-month sale amount $173,550.00 Sale of 3,471 Moderna common shares on 06/04/2026

Past 3-month shares sold 3,471 shares Common shares sold on 06/04/2026 by Shannon Klinger

Key Terms

Rule 144, stock option exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 09/01/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for Shannon Klinger"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Moderna, Inc. (MRNA)?

It discloses that officer Shannon Thyme Klinger filed a Rule 144 notice to sell 3,471 shares of Moderna common stock to be acquired via stock option exercise and sold for cash on or after 09/01/2026, through Fidelity Brokerage Services LLC.

How many Moderna (MRNA) shares are referenced for planned sale?

The notice references 3,471 common shares of Moderna, Inc. These shares are tied to a planned stock option exercise with an intended sale date of 09/01/2026 for cash.

What prior sales by Shannon Klinger in MRNA are reported?

The filing reports that 3,471 common shares of Moderna were sold on 06/04/2026 for a stated total price of $173,550.00. This appears under the section for securities sold during the past three months.

How many Moderna (MRNA) shares are outstanding according to the notice?

The notice states that there are 399,235,889 Moderna common shares outstanding as of 09/01/2026. This figure serves as an outstanding share count baseline, separate from the 3,471 shares referenced for sale.

Who is executing the planned MRNA transactions under the Form 144?

The Form 144 identifies Fidelity Brokerage Services LLC as the broker for the Moderna common stock, with the signature by /s/ Wade Moss as a duly authorized representative and attorney-in-fact for Shannon Klinger.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 11:22 AM EDT Accepted by SEC EDGAR 09/01/2026 - 11:22 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001866132
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Moderna, Inc.
SEC File Number	001-38753
Address of Issuer	325 BINNEY STREET CAMBRIDGE MASSACHUSETTS 02142
Phone	6177146500
Name of Person for Whose Account the Securities are To Be Sold	Klinger Shannon Thyme
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3471	485766.45	399235889	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Stock Option Exercise	Issuer			3471	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shannon Klinger 325 Binney Street Cambridge MA 02142	Common	06/04/2026	3471	173550.00

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Shannon Klinger
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)